Kornimate/medical-research-clean huggingface dataset:
video-assisted informed consent for cataract surgery

Conditions: Cataract; Surgery

Summary: the investigators will investigate whether video-assisted informed consent is superior to routine discussion for cataract patients about risks, benefits and alternatives to receiving phacoemulsification cataract extract and intraocular lens implantation, and will determine whether video-assisted informed consent can reduce the work load of physicians.

patients with age-related cataract who scheduled for elective phacoemulsification cataract extract and intraocular lens implantation surgery and their physicians who on charge of these patients will be enrolled in the study. patients will be randomized to the video assistance group watched a video in cantonese or mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians. the control group will receive traditional verbal information and discussion from their physicians. a questionnaire for patients will be administered to assess the comprehension and satisfaction with the informed consent process before surgery.

Eligibility criteria:
inclusion criteria: patients with age-related cataract scheduled for elective phacoemulsification and intraocular lens implantation for the first time in department of ophthalmology, affiliated hospital of guangdong medical college will be recruited in this study. recruited patients shall own normal intelligence and understanding capability and their best corrected visual acuity more than 0.1 in either eye. exclusion criteria: patients who have undergone previously cataract surgery or whose best corrected visual acuity is lower than 0.1 in either eye or patients who complicated with complex other eye diseases such as uveitis and retinal detachment or patients whose language is not cantonese or mandarin will be excluded from this study.

Keywords: cataract surgery consent process video-assisted
effect of early antiviral therapy on duration of cough in flu patients

Conditions: Influenza Virus Infection

Summary: this study mainly focused on the effect of early antiviral treatment on the duration of cough in influenza patients.investigators conducted an early investigation of patients with positive influenza virus and asked whether patients used antiviral drugs in the early stages. according to the use of drugs, patients were divided into oral oseltamivir group, oral lotus phlegm group and other groups, and investigators will collected inspection information and medication status,during the treatment period of patients.

cough is a common symptom of respiratory diseases and helps to clear respiratory secretions and harmful factors, but frequent severe coughing has a serious impact on the patient's work, life and social activities. upper respiratory tract viral infection is a common cause of coughing. many patients have a long duration of cough after suffering from flu. cough can last for several weeks, and most often have irritating dry cough or a small amount of white mucus sputum. this type of cough is also often referred to as "subacute cough" or "post-infection cough." the mechanisms that cause this cough have not been fully elucidated, and the effect of conventional treatment is not good, and chest imaging has no obvious abnormalities. the use of large amounts of antibiotics is ineffective or ineffective. antihistamine h1 receptor antagonists and central antitussives are often only effective or ineffective in the short term. the effects of various bronchodilators and even hormone drugs are not clear. due to the poor efficacy of multiple treatments, patients are repeatedly subjected to various tests, which not only increases the pain but also aggravates the economic burden. therefore, it is necessary to further clarify the causes and treatment measures of post-influenza cough patients.

Eligibility criteria:
inclusion criteria: for patients with flu-free flu, cough for at least one week. 1. in line with the flu etiological diagnostic criteria: according to the guidelines set by the national health and health committee, the diagnosis is based on etiological screening methods or confirmed methods; ages 18 to 70 years. 2. there are no influenza complications such as acute lower respiratory tract infection, tonsillitis, sinusitis, otitis media, myocarditis, etc. 3. it is usually healthy and there are no chronic underlying diseases such as hypertension and diabetes. 4. treating with cough as the main symptom, the cough lasts for at least one week and the chest radiograph is normal. 5. signed informed consent. exclusion criteria: 1. suspected flu patients who have not received the flu etiology test; 2. there is a clear comorbid disease (combined with other sites of acute bacterial or viral infections); 3. there is a clear cough caused by other reasons; 4. with severe liver and kidney dysfunction; 5. pregnant women.

Keywords: influenza antiviral treatment cough oseltamivir capsule lotus clear capsule
a study of olynth saline/ectomed nasal drops/spray based upon previous usage

Conditions: Common Cold; Sinusitis; Hypersensitivity

Summary: the purpose of this study is to proactively collect customer feedback on the performance aspects and risk factors of olynth nasal saline drops/spray and olynth ectomed nasal spray.


Eligibility criteria:
inclusion criteria: * aged 18 years or older who has personally used or administered the nasal drops/spray to a child * has personally used or administered to a child, the nasal drops/spray at least once within the past 6 months * able to read, write, speak, and understand german * has internet access to complete an on-line survey * intends to complete the survey * individual has signed the informed consent document (icd) exclusion criteria: - is an employee/contractor or immediate family member of the principal investigator (pi), schlesinger group, product perceptions limited (ppl) insights or sponsor of this study
pegylated interferon alfa-2b versus interferon alfa therapy in adult essential thrombocythemia

Conditions: Essential Thrombocytopenia

Summary: objectives: to compare the efficacy and safety in adult patients (≥18 years) diagnosed as essential thrombocythemia treated with the pegylated interferon alfa-2b vs. interferon alfa. study design: a prospective, open-label, multicenter, randomized controlled clinical trial.

this is a prospective, open-label, multicenter, randomized controlled clinical trial between interferon alfa and pegylated interferon alfa-2b in adult essential thrombocythemia (≥18 years). patients will be randomly divided into the following two treatment groups: 1. recombinant interferon alpha, with an initial dose of 300 wu three times a week. other interferons that have been listed can be used if recombinant interferon alpha (300 wu) is not available. 2. pegylated interferon alfa-2b, with an initial dose of 135 ug at week 0 , and then 180 ug once a week from week 1 to week 52. the dosage will be adjusted according to the results of laboratory examinations and patient tolerance. the patient will be transferred to the other group if intolerance or resistance occurs.

Eligibility criteria:
inclusion criteria: * ≥18 years old. * male or female. * diagnosis of essential thrombocythemia according to the 2016 world health organization criteria. * those who have not use interferon within 4 weeks before the first medication. * patients with indications for cytoreductive therapy. * men and women with reproductive potential, as well as all women with menopause less than 2 years, must agree to use acceptable contraceptive methods until 28 days after the last dose of study drug, and women must agree not to breastfeed during the study period. * voluntary written informed consent. exclusion criteria: * resistance, or intolerance, or any contraindications to interferon. * patients with active thrombosis or active bleeding. * neutrophil count \< 1.0x10\^9/l. * hemoglobin \< 11g/dl for male, or \< 10g/dl for female. * poor control of thyroid dysfunction. * patients with a prior malignancy within the last 3 years. * patients with severe cardiac or pulmonary dysfunction. * severe renal damage (creatinine clearance \< 30 ml / min). * severe liver dysfunction (alt or ast \> 2.5×uln). * patients with hepatitis b virus, hepatitis c virus replication or hiv infection. * patients with a history of drug / alcohol abuse (within 2 years before the study). * patients that have participated in other experimental researches within one month before enrollment. * history of psychiatric disorder. * any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.

Keywords: essential thrombocytopenia interferon alfa pegylated interferon alfa-2b efficacy safety
the value of molecular residual disease monitoring based on ctdna in resected pancreatic cancer

Conditions: Pancreatic Cancer; Resectable Carcinoma

Summary: the goal of this clinical trial is to explore the value of molecular residual disease (mrd) monitoring based on ctdna in resected pancreatic cancer. the main questions it aims to answer are: * prognostic value of baseline mrd; * the role of mrd dynamic changes after treatment in guiding treatment. peripheral blood derived from participants will be obtained for mrd test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.


Eligibility criteria:
inclusion criteria: * patients with pancreatic cancer who had undergone curative-intent surgery (r0 or r1 resection); * both sexes, age ≥18 years old; * ecog performance status score ≤2; * the expected survival time was ≥3 months. exclusion criteria: * a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; * treated with any systemic antitumor treatment before first-line chemotherapy onset; * died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; * combined with other primary malignances.
efficacy of the administration of melatonin 5mg in the prevention of delirium in older adults hospitalized in the emergency department

Conditions: Delirium in Old Age

Summary: this study evaluates the efficacy of melatonin 5mg in the prevention of delirium in the older adults in emergency department. half of the participants will receive melatonin 5mg and the other half will use a starch-based placebo.

melatonia is useful for the treatment of sleep disorders due to the interruption of the circadian rhythm, secondary to alterations caused by the environment. the doses of 5 to 10mg oral or sublingual can improve the quality of the sleep-wake cycle and alertness in short-term use. mechanism of action of melatonin are: 1. binding to membrane receptors: mt1 and mt2 coupled to g protein 2. - union to nuclear receptors. 3. - interaction with cytosolic proteins. 4. - antioxidant of direct and indirect action. 5. - interaction with mitochondria. melatonin circulates 80% bound to albumin and the rest in free form in plasma, 85-90% is metabolized by 6-hydroxymelatonin in the liver, which is then conjugated with sulfuric acid (70-80%) or glucuronic ( 5-3%), and is excreted in urine and feces. melatonin and its metabolites act as catalytic antioxidants to safeguard mitochondrial electron transfer reactions, therefore, increases the efficiency of energy metabolism. melatonin synthesis decreases significantly as age progresses and changes in the circadian cycle have been associated with accelerated aging.

Eligibility criteria:
inclusion criteria: * men and women over 60 who enter the emergency department with a stay in the ward for more than 8 hours and who will remain hospitalized for more than 48 hours due to admission pathology. * patients who agree to participate in the study by signing an informed consent (signature by patient and / or family member). exclusion criteria: * patients with a history of dementia or previous neurological diseases. * patients with a history of psychiatric disorder. * patients diagnosed with any type of liver disease. * warfarin treatment. * delirium data on admission to the emergency department. * patients under invasive mechanical ventilation and sedation.
spinchip hs-ctni sample type validation

Conditions: Acute Myocardial Infarction

Summary: during a heart attack, the protein troponin i is released from the heart muscle into the bloodstream. measurements of cardiac troponin in blood are used as an aid in the diagnosis of heart attack. the spinchip hs-ctni test is a new high-sensitive test for measuring the amount of cardiac troponin i in the bloodstream as an aid in the diagnosis of heart attack. the purpose of this study is to demonstrate that different types of blood samples (finger prick, venous whole blood and plasma) return comparable results when analysed using the spinchip hs-ctni test. blood samples from at least 150 patients will be analyzed and the testing will be carried out by healthcare personnel.

cardiac troponins are widely used as a biomarker to aid in the diagnosis of acute myocardial infarction (ami). these structural proteins are essential in regulating contraction in cardiac muscle cells, and they are sensitive and specific biochemical markers of myocardial damage. during a heart attack, cardiac muscle cells are injured and release the cardiac marker troponin i (ctni) into the bloodstream. high-sensitive troponin tests may detect the increase of cardiac troponin in blood within hours after the symptoms of a heart attack has started. the spinchip high-sensitivity cardiac troponin i (hs-ctni) test is a new high-sensitive test for measuring troponin i in blood samples, and the analysis may be performed close to the patient (near-patient test). the results may be obtained within 10 minutes, compared to approximately 1 hour for normal laboratory analysis. the spinchip platform consists of the spinchip hs-ctni test and the spinchip analyzer and may be used at the emergency department to evaluate patients presenting with symptoms of acute myocardial infarction (chest pain). the test can use blood from finger prick or venous blood samples, either as whole blood or separated into plasma. the purpose of this study is to demonstrate that different sample types (finger prick, venous whole blood or plasma) give comparable results when analysed using the spinchip hs-ctni test when the testing is performed by healthcare professionals. samples from minimum 150 patients with troponin levels covering the measuring range of the spinchip hs-ctni test will be collected and analysed.

Eligibility criteria:
inclusion criteria: * able and willing to provide signed written informed consent * subjects \>18 years old * clinical cardiac troponin t concentration available exclusion criteria: * cognitive impairment precluding informed consent * self-reported pregnancy * general clinical condition which affects the patient in a major way and the patient is considered to be in an unstable clinical condition * previously included in the study with a sample within the measuring range of the spinchip hs-ctni test

Keywords: acute myocardial infarction high-sensitive point of care troponin i near-patient test heart attack
a study to investigate the pharmacodynamic effects of ct327 on intra-dermal nerve growth factor (ngf) and evoked pain responses, in healthy male volunteers

Conditions: Neuropathic Pain

Summary: the primary objective of this study is to compare the effect of ct327 to placebo against experimental induced superficial, deep and hyperalgesic pain. the secondary objectives are to elucidate the mechanisms of ct327 using experimental pain models.


Eligibility criteria:
inclusion criteria: * subjects must be able to understand the contents of the study, comply with the study and willing to sign informed consent * subjects must be free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory and other tests * all male subjects must take adequate contraceptive precautions during the course of the study and for 30 days after their participation in the study has ended exclusion criteria: * participation in other clinical studies within 3 months before screening * scheduled for surgery, medical treatment or any hospital admission that would fall within the study * use of strong painkillers * use of any analgesic within 24 hours before start of study * use of a regular course of prescribed medication and/or herbal medicine * the presence of lesions, significant scars, cuts, wounds, dermal abnormalities, tattoos or naevi in the test areas * a past history of contact dermatitis, psoriasis or keloid * any clinically significant ecg abnormality at screening * a history of drug or other allergy that contraindicates his participation. * regular or average consumption of more than 21 units of alcohol per week (one unit of alcohol equals approximately 250 ml of beer, 125 ml of wine or 20 ml of spirits). * smokes more than five cigarettes (on average) per day, or had been a smoker of more than 5 cigarettes (on average) per day within the 3 months prior to screening. * a known history of drug or alcohol abuse. * as a result of the medical screening process, the pi or medical delegate considers the subject unfit for the study. * use of any prescription medication within 2 weeks or 5 half-lives (whichever is longer) of dosing. * use of non-prescription medication (e.g. aspirin, vitamins and herbal and dietary supplements) within 7 days prior to dosing, or 14 days if the medication contained grapefruit/ grapefruit juice or st john's wort.
integrative analysis of crc liver metastasis

Conditions: Metastasis

Summary: the investigators will perform integrative analysis of crc liver metastasis

the investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (crc) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (snp) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of crc characterized previously by the cancer genome atlas (tcga) to conduct integrated proteogenomic analyses.

Eligibility criteria:
inclusion criteria: * age ≤ 75 years with histologically proven crc * no severe major organ dysfunction * who performance status of 0 or 1 * no prior cancer chemotherapy exclusion criteria: * age ≥ 76 * severe major organ dysfunction * world health organization (who) performance status of \>1 * prior cancer chemotherapy

Keywords: crc liver metastasis
epidemiological profile of children with early caries.

Conditions: Dental Caries

Summary: the objective of the study is to determine the different profiles of patients with early caries consulting at the lille chu and to analyse the characteristics associated with the severity of the pathology. the data will be collected using a simple clinical examination of the child and a survey of the parent using a questionnaire. the typology of patients with early caries will be analysed according to the predefined variables collected using the questionnaire via a main component analysis in order to study the links between these variables. at the same time, a hierarchical classification analysis will be carried out to study the existence of homogeneous sub-groups of individuals in regard to the early caries. these sub-groups will be described


Eligibility criteria:
inclusion criteria: * be a child under the age of 6, * having been diagnosed with early caries * be accompanied by at least one parent (the mother or father). * be affiliated to a social security exclusion criteria: * be a child over the age of 6
improving low aspects stroke thrombectomy

Conditions: Acute Ischemic Stroke

Summary: improving low aspects stroke thromectomy (i-last) is an academic, independent, prospective, multicenter, observational registry study. consecutive patients treated with endovascular stroke treatment will be enrolled in german stroke centers. patients receive regular care and data will be collected as part of clinical routine. baseline clinical and procedural information as well clinical follow-up information during in-hospital stay, and up to 90 days of stroke onset are collected. data collected include demographics, national institute of health stroke scale (nihss) on admission, pre-treatment aspects, information on timing and success of interventional treatment, procedural complications, intracranial hemorrhage, and functional outcome. advanced imaging biomarkers will be tested and validated aiming to improve treatment selection and outcome prediction of patients presenting with extensive baseline infarction.

this study aims to investigate the role of advanced imaging biomarkers in patients with large early infarct, in particular quantitative lesion water uptake (minnerup et al. annals of neurology 2016), arterial and venous collateral circulation (faizy et al. radiology 2021), and multivariate ctp-derived parameters (kemmling et al. jcbfm 2015). the goal is to use these imaging biomarkers as specific selection criterion to predict clinical benefit after reperfusion despite extensive baseline infarct lesions, also as a method of monitoring adjuvant neuroprotective agents after reperfusion therapy (for instance anti-edematous medication).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute ischemic stroke * aspects of 0-5 * confirmed diagnosis of persistent occlusion of terminal carotid artery, middle cerebral artery (m1 or m2), or basilar artery consistent with symptoms * age \>18 years * ethic approval in process exclusion criteria: none
a real-world evidence study of bnt162b2 mrna covid-19 vaccine in brazil

Conditions: Covid19

Summary: the present test-negative design study aims to estimate the real-world effectiveness of pfizer-biontech bnt162b2 mrna vaccine on symptomatic sars-cov-2 infection and its consequences following a mass vaccination campaign in the city of toledo in southern brazil. individuals aged 12 years or older who seek the public healthcare system with symptoms suggestive covid-19 will be enrolled. participants with a positive polymerase chain reaction (pcr) test for sars-cov-2 will be classified as cases, and those with negative pcr test for sars-cov-2 will be classified as controls. cases will be followed-up for a period of one year by means of structured telephone interviews.


Eligibility criteria:
inclusion criteria: * age ≥ 12 years old; * resident of toledo city; * seeking care in the public healthcare system with symptoms suggestive of covid-19 defined as follows: 1) ari symptoms (nasal congestion, rhinorrhea, anosmia, sore throat, hoarseness, new or increased-from-baseline cough, sputum production, dyspnea, wheezing, myalgia) or 2) admitting diagnosis suggestive of ari (pneumonia, upper respiratory infection, bronchitis, influenza, cough, asthma, viral respiratory illness, respiratory distress, and/or respiratory failure). * nasal sample for sars-cov-2 diagnosis obtained as standard of care. exclusion criteria: * sars-cov-2-directed antiviral treatment within the past 30 days; * covid-19 monoclonal antibody therapy within the past 90 days; * covid-19 convalescent serum therapy within the past 90 days; * lack of consent to participate.

Keywords: covid-19 mass vaccination